Navigation Links
Insmed CEO to Present at Drug Discovery & Development Conference
Date:7/25/2008

CEO Geoffrey Allan Will Discuss Company's IPLEX(TM) Program in Myotonic

Muscular Dystrophy

RICHMOND, Va., July 25 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM) a developer of follow-on biologics and biopharmaceuticals, today announced that Geoffrey Allan, Ph.D., CEO of Insmed, will present at IBC's 13th Annual Drug Discovery and Development of Innovative Therapeutics on Thursday, August 7th, 2008 at 9:25 AM ET.

Dr. Allan will be participating in the Orphan Diseases track of the conference and his presentation will be entitled, "Myotonic Muscular Dystrophy - A Major Unmet Medical Need." He will present Insmed's progress with its Phase II trial for IPLEX(TM) in Myotonic Muscular Dystrophy. The trial, which has seen strong patient and physician interest, is now fully enrolled. It is a six month, randomized, double-blind, placebo-controlled trial being conducted at 13 research centers across the U.S.

The conference will be held from August 4th to August 7th, 2008, at the World Trade Center Boston and the Seaport Hotel in Boston, MA.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause act
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insmed to Host Second Quarter 2008 Conference Call
2. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
3. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
4. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
5. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
6. Insmed Announces First Quarter 2008 Financial Results
7. Insmed to Present at CBI Follow-On Biologics Conference
8. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
11. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/21/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 30, 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A ... Summary:Three-months ended September 30, , Nine-months ended ... 2014 , 2013 , 2014 ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... November 17, 2014 Cirrascale ... architecture blade-based and rackmount computing infrastructure, today announced ... dual-GPU accelerator throughout its GPU-enabled blade server and ... the company’s latest proprietary 80-lane Gen3 PCIe switch-enabled ... NVIDIA Tesla K80 dual-GPU accelerator cards in a ...
(Date:11/18/2014)... November 18, 2014 Alanda Software, ... Transparency Reporting solutions, announced today that a top ... its Consummate Provider™ solution in both the U.S. ... Global, SaaS based, Data Quality remediation portal, designed ... third party Providers improve their ability to capture, ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... Chromatography and Mass Spectrometry Application Report , ... Equine serum Acepromazine , Gargi Choudhary, ... Wayne Skinner and Scott Stanley, University of California, ... Acepromazine is widely used as a sedative in ...
... Application Note , Kevin J. McHale, ... Thermo Electron Corporation, Somerset, NJ, USA , ... Acrylamide has been identified as a potential human carcinogen. ... but acrylamide was recently discovered to be present at significant levels in ...
... James Batchelor, and Ed Alderman , Applied ... Kelly M. Clark, Joseph A. Hensley and Robert P. Weisbein ... , Jennifer L. Halcome and George R. Halley ... CO , Introduction , ...
Cached Biology Technology:Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 2Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 3Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 4Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 2Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 3Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 4Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 5Quantitation of Acrylamide in Food Samples on the Finnigan TSQ Quantum Discovery by LC/APCI-MS/MS 6Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000 2Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000 3Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000 4
(Date:11/5/2014)... Kelly Redmond has dedicated his career to understanding ... a general audience. , As deputy director and ... at Nevada,s Desert Research Institute, Redmond has more ... application and dissemination of climate data to the ... Meeting in San Francisco on December 15-19, 2014 ...
(Date:11/4/2014)... of Utah engineers developed the first room-temperature fuel cell ... without needing to ignite the fuel. These new fuel ... power and sensors. , A study of the new ... journal ACS Catalysis . , Fuel cells convert ... fuel and an oxygen-rich source such as air. If ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Jet-fueled electricity at room temperature 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... - At a glance, a painting by Jackson Pollock (1912󈞤) ... on a canvas. A quantitative analysis of Pollock,s streams, ... at Boston College, reveals, however, that the artist had to ... the way that he did. The finding, published in ...
... Mensenchymal stem cells (MSCs), multipotent cells identified in ... be therapeutically effective in the immunosuppression of T-cells, the ... and suppressing chronic airway inflammation in some asthma cases. ... applications, they are cultured in fetal bovine serum. , ...
... has been followed by a decline in fertility rates in ... first concerted rise in fertility rates in the developed world ... "In a new study, scientists from the Vienna Institute ... the International Institute for Applied Systems Analysis (IIASA) identify that ...
Cached Biology News:Jackson Pollock, artist and physicist? 2Jackson Pollock, artist and physicist? 3Serum-free cultures help transplanted MSCs improve efficacy 2Fertility rates affected by global economic crisis 2
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... STAR3000 HISTAR detection systems provide linking ... used with species specific primary antibodies ... specimens. Visualisation is accomplished using an ... novel polymer labelling technology. Secondary antibodies ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
... AmpliTaq DNA Polymerase is ... the PCR process, a testimony to its ... activity profile makes it ideal for PCR ... to guarantee reproducible results. ,, AmpliTaq ...
Biology Products: